BACKGROUND: Pulmonary hypertension and chronic thromboembolic pulmonary hypertension may develop after a pulmonary embolism event. A ventilation-perfusion scan is recommended as a first-line modality for suspected chronic thromboembolic pulmonary hypertension. In this study, we determined the prevalence of pulmonary hypertension following incident pulmonary embolism and the disease-monitoring patterns in this population. METHODS: We conducted a retrospective claims database analysis of incident pulmonary embolism cases (July 1, 2010 to September 30, 2011) and extracted data for 1 year prior to and 2 years after the incident pulmonary embolism event. Data were analyzed for diagnoses and symptoms related to pulmonary hypertension, claims consistent with other heart or lung diseases, diagnostic imaging tests, and time to first diagnostic imaging test post pulmonary embolism. RESULTS: Of the 7068 incident pulmonary embolism patients that met eligibility criteria, 87% had a claim for a pulmonary hypertension-related symptom and 7.6% had a claim for pulmonary hypertension during follow-up. Only 55% of all pulmonary embolism patients had diagnostic procedural claim(s) post pulmonary embolism: echocardiogram, 47%; computed tomographic angiography, 20%; ventilation-perfusion scan, 6%; and right heart catheterization or pulmonary angiography, <1%. The mean time from pulmonary embolism diagnosis to first screening test was 131 days. CONCLUSIONS: Despite exhibiting pulmonary hypertension-related symptoms, many pulmonary embolism patients did not undergo imaging tests that could diagnose pulmonary hypertension or chronic thromboembolic pulmonary hypertension. This study suggests that physician education about the risk of pulmonary hypertension and chronic thromboembolic pulmonary hypertension after pulmonary embolism may need to be improved.
BACKGROUND:Pulmonary hypertension and chronic thromboembolic pulmonary hypertension may develop after a pulmonary embolism event. A ventilation-perfusion scan is recommended as a first-line modality for suspected chronic thromboembolic pulmonary hypertension. In this study, we determined the prevalence of pulmonary hypertension following incident pulmonary embolism and the disease-monitoring patterns in this population. METHODS: We conducted a retrospective claims database analysis of incident pulmonary embolism cases (July 1, 2010 to September 30, 2011) and extracted data for 1 year prior to and 2 years after the incident pulmonary embolism event. Data were analyzed for diagnoses and symptoms related to pulmonary hypertension, claims consistent with other heart or lung diseases, diagnostic imaging tests, and time to first diagnostic imaging test post pulmonary embolism. RESULTS: Of the 7068 incident pulmonary embolismpatients that met eligibility criteria, 87% had a claim for a pulmonary hypertension-related symptom and 7.6% had a claim for pulmonary hypertension during follow-up. Only 55% of all pulmonary embolismpatients had diagnostic procedural claim(s) post pulmonary embolism: echocardiogram, 47%; computed tomographic angiography, 20%; ventilation-perfusion scan, 6%; and right heart catheterization or pulmonary angiography, <1%. The mean time from pulmonary embolism diagnosis to first screening test was 131 days. CONCLUSIONS: Despite exhibiting pulmonary hypertension-related symptoms, many pulmonary embolismpatients did not undergo imaging tests that could diagnose pulmonary hypertension or chronic thromboembolic pulmonary hypertension. This study suggests that physician education about the risk of pulmonary hypertension and chronic thromboembolic pulmonary hypertension after pulmonary embolism may need to be improved.
Authors: George A Alba; Andriy O Samokhin; Rui-Sheng Wang; Ying-Yi Zhang; Bradley M Wertheim; Elena Arons; Edward A Greenfield; Martina H Lundberg Slingsby; Julia R Ceglowski; Kathleen J Haley; Frederick P Bowman; Yen-Rei Yu; John C Haney; George Eng; Richard N Mitchell; Anthony Sheets; Sara O Vargas; Sachiko Seo; Richard N Channick; Peter J Leary; Sudarshan Rajagopal; Joseph Loscalzo; Elisabeth M Battinelli; Bradley A Maron Journal: Am J Respir Crit Care Med Date: 2021-06-15 Impact factor: 21.405
Authors: Lukasz A Myc; Jigna N Solanki; Andrew J Barros; Nebil Nuradin; Matthew G Nevulis; Kranthikiran Earasi; Emily D Richardson; Shawn C Tsutsui; Kyle B Enfield; Nicholas R Teman; Ziv J Haskal; Sula Mazimba; Jamie L W Kennedy; Andrew D Mihalek; Aditya M Sharma; Alexandra Kadl Journal: Respir Res Date: 2020-06-22
Authors: Simon Teal; William R Auger; Rodney J Hughes; Dena Rosen Ramey; Kelly S Lewis; Gerald O'Brien; Avin Yaldo; Tanya M Burton; Tim Bancroft; Jerry Seare; Joerg Fabian Journal: Pulm Circ Date: 2018-11-13 Impact factor: 3.017
Authors: Belinda Rivera-Lebron; Michael McDaniel; Kamran Ahrar; Abdulah Alrifai; David M Dudzinski; Christina Fanola; Danielle Blais; David Janicke; Roman Melamed; Kerry Mohrien; Elizabeth Rozycki; Charles B Ross; Andrew J Klein; Parth Rali; Nicholas R Teman; Leoara Yarboro; Eugene Ichinose; Aditya M Sharma; Jason A Bartos; Mahir Elder; Brent Keeling; Harold Palevsky; Soophia Naydenov; Parijat Sen; Nancy Amoroso; Josanna M Rodriguez-Lopez; George A Davis; Rachel Rosovsky; Kenneth Rosenfield; Christopher Kabrhel; James Horowitz; Jay S Giri; Victor Tapson; Richard Channick Journal: Clin Appl Thromb Hemost Date: 2019 Jan-Dec Impact factor: 2.389
Authors: Nick H Kim; Marion Delcroix; Xavier Jais; Michael M Madani; Hiromi Matsubara; Eckhard Mayer; Takeshi Ogo; Victor F Tapson; Hossein-Ardeschir Ghofrani; David P Jenkins Journal: Eur Respir J Date: 2019-01-24 Impact factor: 16.671
Authors: Kim A Ma; Susan R Kahn; Arash Akaberi; Carole Dennie; Christopher Rush; John T Granton; David Anderson; Philip S Wells; Marc A Rodger; Susan Solymoss; Michael J Kovacs; Lawrence Rudski; Avi Shimony; Paul Hernandez; Shawn D Aaron; Elena Pena; Gad Abikhzer; Andrew M Hirsch Journal: Res Pract Thromb Haemost Date: 2018-06-17